Abstract: This invention relates to nutritional compositions comprising at least one N-acetylated oligosaccharide for use in the promotion of the development and/or of the growth of the intestinal muscles, in the promotion of contractile capacity and/or the motility in the intestine, in the promotion of enteral feeding tolerance and in prevention and/or treatment of small intestinal bacterial overgrowth (SIBO) in an infant, a young child or, when the composition is a growing-up milk, in a child.

Abstract: This invention relates to compositions for use in the promotion of the development and/or of the growth of the surface area of the small intestine and in the associated improvement of the digestive capacity in an infant or in a young child.

Abstract: Methods and uses of B. longum strain ATCC-999 for the treatment or prophylaxis of infant colic are disclosed.

Abstract: A method, in one embodiment, includes administering to a non-infant human an effective amount of a combination of the human milk oligosaccharides (“HMO”s) 2?-FL and DFL, where the amount of the combination of HMOs is effective for modulating the microbiota of the non-infant human and reducing one or more post-treatment condition such as pain and/or a perception of visceral pain in the non-infant human.

Abstract: The present invention refers to nutritional composition comprising sn-1(3) monoacylglycerols for use in the prevention/treatment of growth delay and/or in the promotion of growth in an infant or in a child like a young child, such as a preterm and/or low birth weight infants.

Abstract: The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Abstract: The invention relates to a nutrition composition with promoting or inducing a gut microbiota that is closer to infants fed exclusively with human breast milk, in comparison to infant fed with conventional nutritional composition. The composition is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. The infants can be fed during 2, 4, or 6 months and the composition can be an infant formula. The composition promotes a healthy intestinal flora and has beneficial long and short terms effects.

Abstract: Nutritional compositions are provided that comprise a fructo-oligosaccharaide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut micro biota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.

Abstract: The present invention generally relates to the field of probiotics, and in particular to preventing and/or treating inflammatory and infectious disorders, for example by boosting the endogenous antimicrobial defences. One embodiment of the present invention is a composition comprising a combination of L. johnsonii (La1, NCC 533, deposit number CNCM I-1225) and Bifidobacterium longum NCC2705 (deposit number CNCM I-2618). This composition may be used in the treatment or prevention of disorders related to the immune system including infections.

Abstract: The present invention refers to nutritional composition comprising sn-1(3) monoacylglycerols for use in the treatment or prevention of maldigestion and/or malabsorption in an infant or young child. It also refers to a nutritional composition comprising sn-1(3) monoacylglycerols for use to increase lipid (e.g. fatty acids) absorption/delivery and/or to increase the energy or the mineral bioavailability in an infant or young child. The infant or young child may have a gut immaturity and/or a reduced enteral feeding tolerance. They may also be pretermand/or low birth weight.

Abstract: The present invention relates to synthetic nutritional compositions, especially infant formula compositions, with a low content of medium-chain fatty acids (or MFCAs) and particularly in specific proportions. The invention also relates to the use of said compositions to promote liver and/or gut maturation in infants or young children and/or to reduce the risk of liver and/or gut disease in infants or young children.

Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention can help parents to protect their children from such upper respiratory tract infections.

Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections.

Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from gastro-intestinal infections, in particular diarrhea. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of gastrointestinal infections in children.

Abstract: Nutritional compositions are provided that comprise a fructo-oligosaccharaide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut micro biota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.

Abstract: The present disclosure relates to nutritional compositions comprising a fructo-oligosaccharide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut microbiota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.

Abstract: This invention relates to a nutritional formulation comprising an n3 long-chain polyunsaturated fatty acid (LC-PUFA), a prebiotic fiber and a probiotic bacterial strain which ingredients act together in a synergistic fashion to promote catch-up growth in young mammals whose growth has been retarded because the young mammal has been subjected to physical or mental stress.

Abstract: This invention relates to the use of a probiotic bacterial strain in the manufacture of a medicament or therapeutic nutritional composition for improving the maturation of sleep patterns in infants, young children or young animals and/or for reducing sleep disturbances and/or improving sleep patterns in humans or animals at any age.

Abstract: This invention relates to the use of a probiotic bacterial strain in the manufacture of a medicament or therapeutic nutritional composition for improving the maturation of sleep patterns in infants, young children or young animals and/or for reducing sleep disturbances and/or improving sleep patterns in humans or animals at any age.

Abstract: This invention relates to the use of a probiotic bacterial strain in the manufacture of a medicament or therapeutic nutritional composition for improving the maturation of sleep patterns in infants, young children or young animals and/or for reducing sleep disturbances and/or improving sleep patterns in humans or animals at any age.